APO Research
Talk to an analyst

APO RESEARCH · REPORT

GABAB Receptor Agonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global GABAB Receptor Agonists Market Outlook and Growth Opportunities 2026

20 December 2025196 pages

Choose your research edition.

Industry ResearchGABAB Receptor Agonists Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal GABAB Receptor Agonists Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal GABAB Receptor Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GABAB Receptor Agonists Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal GABAB Receptor Agonists Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global GABAB Receptor Agonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for GABAB Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GABAB Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GABAB Receptor Agonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the GABAB Receptor Agonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the GABAB Receptor Agonists market include Xi'an Libang Pharmaceuticals, Xi'an Hanfeng Pharmaceuticals, Sun Pharma, Hemony Pharmaceutical, Sichuan Ren'an Pharmaceuticals, Novartis, Nanjing Haina Pharmaceutical, China Resources Double Crane Pharmaceuticals and Fuan Pharmaceutical Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GABAB Receptor Agonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GABAB Receptor Agonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GABAB Receptor Agonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GABAB Receptor Agonists market size, projected growth trends, production technologies, key applications, and end-use industries.

GABAB Receptor Agonists Segment by Company

Xi'an Libang Pharmaceuticals

Xi'an Hanfeng Pharmaceuticals

Sun Pharma

Hemony Pharmaceutical

Sichuan Ren'an Pharmaceuticals

Novartis

Nanjing Haina Pharmaceutical

China Resources Double Crane Pharmaceuticals

Fuan Pharmaceutical Group

Chengdu Beite

Viatris

Jazz Pharmaceuicals

Hikma

GABAB Receptor Agonists Segment by Type

Baclofen

γ-hydroxybutyrate(GHB)）

GABAB Receptor Agonists Segment by Application

Hospital

Clinic

Other

GABAB Receptor Agonists Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global GABAB Receptor Agonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions GABAB Receptor Agonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify GABAB Receptor Agonists significant trends, drivers, influence factors in global and regions.

6. To analyze GABAB Receptor Agonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GABAB Receptor Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GABAB Receptor Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GABAB Receptor Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GABAB Receptor Agonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GABAB Receptor Agonists industry.

Chapter 3: Detailed analysis of GABAB Receptor Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of GABAB Receptor Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of GABAB Receptor Agonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. GABAB Receptor Agonists Industry Trends Table 2. GABAB Receptor Agonists Industry Drivers Table 3. GABAB Receptor Agonists Industry Opportunities and Challenges Table 4. GABAB Receptor Agonists Industry Restraints Table 5. Global GABAB Receptor Agonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global GABAB Receptor Agonists Revenue Share by Company (2021-2026) Table 7. Global GABAB Receptor Agonists Sales Volume by Company (K Units) & (2021-2026) Table 8. Global GABAB Receptor Agonists Sales Volume Share by Company (2021-2026) Table 9. Global GABAB Receptor Agonists Average Price (US$/Unit) of Company (2021-2026) Table 10. Global GABAB Receptor Agonists Company Ranking, (2024-2026) & (USD Million) Table 11. Global GABAB Receptor Agonists Key Company Manufacturing Base & Headquarters Table 12. Global GABAB Receptor Agonists Company, Product Type & Application Table 13. Global GABAB Receptor Agonists Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global GABAB Receptor Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Baclofen Table 18. Significant Companies of γ-hydroxybutyrate(GHB)） Table 19. Global GABAB Receptor Agonists Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global GABAB Receptor Agonists Sales Volume by Type (2021-2026) & (K Units) Table 21. Global GABAB Receptor Agonists Sales Volume by Type (2027-2032) & (K Units) Table 22. Global GABAB Receptor Agonists Sales Volume Share by Type (2021-2026) Table 23. Global GABAB Receptor Agonists Sales Volume Share by Type (2027-2032) Table 24. Global GABAB Receptor Agonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global GABAB Receptor Agonists Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global GABAB Receptor Agonists Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global GABAB Receptor Agonists Sales Value Share by Type (2021-2026) Table 28. Global GABAB Receptor Agonists Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Other Table 32. Global GABAB Receptor Agonists Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global GABAB Receptor Agonists Sales Volume by Application (2021-2026) & (K Units) Table 34. Global GABAB Receptor Agonists Sales Volume by Application (2027-2032) & (K Units) Table 35. Global GABAB Receptor Agonists Sales Volume Share by Application (2021-2026) Table 36. Global GABAB Receptor Agonists Sales Volume Share by Application (2027-2032) Table 37. Global GABAB Receptor Agonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global GABAB Receptor Agonists Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global GABAB Receptor Agonists Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global GABAB Receptor Agonists Sales Value Share by Application (2021-2026) Table 41. Global GABAB Receptor Agonists Sales Value Share by Application (2027-2032) Table 42. Global GABAB Receptor Agonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global GABAB Receptor Agonists Sales by Region (2021-2026) & (K Units) Table 44. Global GABAB Receptor Agonists Sales Market Share by Region (2021-2026) Table 45. Global GABAB Receptor Agonists Sales by Region (2027-2032) & (K Units) Table 46. Global GABAB Receptor Agonists Sales Market Share by Region (2027-2032) Table 47. Global GABAB Receptor Agonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global GABAB Receptor Agonists Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global GABAB Receptor Agonists Sales Value Share by Region (2021-2026) Table 50. Global GABAB Receptor Agonists Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global GABAB Receptor Agonists Sales Value Share by Region (2027-2032) Table 52. Global GABAB Receptor Agonists Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global GABAB Receptor Agonists Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global GABAB Receptor Agonists Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global GABAB Receptor Agonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global GABAB Receptor Agonists Sales by Country (2021-2026) & (K Units) Table 57. Global GABAB Receptor Agonists Sales Market Share by Country (2021-2026) Table 58. Global GABAB Receptor Agonists Sales by Country (2027-2032) & (K Units) Table 59. Global GABAB Receptor Agonists Sales Market Share by Country (2027-2032) Table 60. Global GABAB Receptor Agonists Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global GABAB Receptor Agonists Sales Value Market Share by Country (2021-2026) Table 62. Global GABAB Receptor Agonists Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global GABAB Receptor Agonists Sales Value Market Share by Country (2027-2032) Table 64. Xi'an Libang Pharmaceuticals Company Information Table 65. Xi'an Libang Pharmaceuticals Business Overview Table 66. Xi'an Libang Pharmaceuticals GABAB Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Xi'an Libang Pharmaceuticals GABAB Receptor Agonists Product Portfolio Table 68. Xi'an Libang Pharmaceuticals Recent Development Table 69. Xi'an Hanfeng Pharmaceuticals Company Information Table 70. Xi'an Hanfeng Pharmaceuticals Business Overview Table 71. Xi'an Hanfeng Pharmaceuticals GABAB Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Xi'an Hanfeng Pharmaceuticals GABAB Receptor Agonists Product Portfolio Table 73. Xi'an Hanfeng Pharmaceuticals Recent Development Table 74. Sun Pharma Company Information Table 75. Sun Pharma Business Overview Table 76. Sun Pharma GABAB Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Sun Pharma GABAB Receptor Agonists Product Portfolio Table 78. Sun Pharma Recent Development Table 79. Hemony Pharmaceutical Company Information Table 80. Hemony Pharmaceutical Business Overview Table 81. Hemony Pharmaceutical GABAB Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Hemony Pharmaceutical GABAB Receptor Agonists Product Portfolio Table 83. Hemony Pharmaceutical Recent Development Table 84. Sichuan Ren'an Pharmaceuticals Company Information Table 85. Sichuan Ren'an Pharmaceuticals Business Overview Table 86. Sichuan Ren'an Pharmaceuticals GABAB Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Sichuan Ren'an Pharmaceuticals GABAB Receptor Agonists Product Portfolio Table 88. Sichuan Ren'an Pharmaceuticals Recent Development Table 89. Novartis Company Information Table 90. Novartis Business Overview Table 91. Novartis GABAB Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Novartis GABAB Receptor Agonists Product Portfolio Table 93. Novartis Recent Development Table 94. Nanjing Haina Pharmaceutical Company Information Table 95. Nanjing Haina Pharmaceutical Business Overview Table 96. Nanjing Haina Pharmaceutical GABAB Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Nanjing Haina Pharmaceutical GABAB Receptor Agonists Product Portfolio Table 98. Nanjing Haina Pharmaceutical Recent Development Table 99. China Resources Double Crane Pharmaceuticals Company Information Table 100. China Resources Double Crane Pharmaceuticals Business Overview Table 101. China Resources Double Crane Pharmaceuticals GABAB Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. China Resources Double Crane Pharmaceuticals GABAB Receptor Agonists Product Portfolio Table 103. China Resources Double Crane Pharmaceuticals Recent Development Table 104. Fuan Pharmaceutical Group Company Information Table 105. Fuan Pharmaceutical Group Business Overview Table 106. Fuan Pharmaceutical Group GABAB Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Fuan Pharmaceutical Group GABAB Receptor Agonists Product Portfolio Table 108. Fuan Pharmaceutical Group Recent Development Table 109. Chengdu Beite Company Information Table 110. Chengdu Beite Business Overview Table 111. Chengdu Beite GABAB Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Chengdu Beite GABAB Receptor Agonists Product Portfolio Table 113. Chengdu Beite Recent Development Table 114. Viatris Company Information Table 115. Viatris Business Overview Table 116. Viatris GABAB Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Viatris GABAB Receptor Agonists Product Portfolio Table 118. Viatris Recent Development Table 119. Jazz Pharmaceuicals Company Information Table 120. Jazz Pharmaceuicals Business Overview Table 121. Jazz Pharmaceuicals GABAB Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Jazz Pharmaceuicals GABAB Receptor Agonists Product Portfolio Table 123. Jazz Pharmaceuicals Recent Development Table 124. Hikma Company Information Table 125. Hikma Business Overview Table 126. Hikma GABAB Receptor Agonists Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Hikma GABAB Receptor Agonists Product Portfolio Table 128. Hikma Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. GABAB Receptor Agonists Distributors List Table 132. GABAB Receptor Agonists Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. GABAB Receptor Agonists Product Image Figure 2. Global GABAB Receptor Agonists Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GABAB Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 4. Global GABAB Receptor Agonists Sales (2021-2032) & (K Units) Figure 5. Global GABAB Receptor Agonists Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global GABAB Receptor Agonists Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Baclofen Image Figure 10. γ-hydroxybutyrate(GHB)） Image Figure 11. Global GABAB Receptor Agonists Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global GABAB Receptor Agonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global GABAB Receptor Agonists Sales Volume Share by Type (2021-2032) Figure 14. Global GABAB Receptor Agonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global GABAB Receptor Agonists Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global GABAB Receptor Agonists Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Other Image Figure 20. Global GABAB Receptor Agonists Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global GABAB Receptor Agonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global GABAB Receptor Agonists Sales Volume Share by Application (2021-2032) Figure 23. Global GABAB Receptor Agonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global GABAB Receptor Agonists Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global GABAB Receptor Agonists Sales Value Share by Application (2021-2032) Figure 26. Global GABAB Receptor Agonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global GABAB Receptor Agonists Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global GABAB Receptor Agonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global GABAB Receptor Agonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America GABAB Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 31. North America GABAB Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe GABAB Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 33. Europe GABAB Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific GABAB Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific GABAB Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America GABAB Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 37. South America GABAB Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa GABAB Receptor Agonists Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa GABAB Receptor Agonists Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt GABAB Receptor Agonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. GABAB Receptor Agonists Value Chain Figure 125. Manufacturing Cost Structure Figure 126. GABAB Receptor Agonists Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Baclofen
  • γ-hydroxybutyrate(GHB)）
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Xi'an Libang Pharmaceuticals
  • Xi'an Hanfeng Pharmaceuticals
  • Sun Pharma
  • Hemony Pharmaceutical
  • Sichuan Ren'an Pharmaceuticals
  • Novartis
  • Nanjing Haina Pharmaceutical
  • China Resources Double Crane Pharmaceuticals
  • Fuan Pharmaceutical Group
  • Chengdu Beite
  • Viatris
  • Jazz Pharmaceuicals
  • Hikma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global GABAB Receptor Agonists Sales Value (2021-2032)
  4. 1.2.2 Global GABAB Receptor Agonists Sales Volume (2021-2032)
  5. 1.2.3 Global GABAB Receptor Agonists Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 GABAB Receptor Agonists Market Dynamics
  1. 2.1 GABAB Receptor Agonists Industry Trends
  2. 2.2 GABAB Receptor Agonists Industry Drivers
  3. 2.3 GABAB Receptor Agonists Industry Opportunities and Challenges
  4. 2.4 GABAB Receptor Agonists Industry Restraints
3 GABAB Receptor Agonists Market by Company
  1. 3.1 Global GABAB Receptor Agonists Company Revenue Ranking in 2025
  2. 3.2 Global GABAB Receptor Agonists Revenue by Company (2021-2026)
  3. 3.3 Global GABAB Receptor Agonists Sales Volume by Company (2021-2026)
  4. 3.4 Global GABAB Receptor Agonists Average Price by Company (2021-2026)
  5. 3.5 Global GABAB Receptor Agonists Company Ranking (2024-2026)
  6. 3.6 Global GABAB Receptor Agonists Company Manufacturing Base and Headquarters
  7. 3.7 Global GABAB Receptor Agonists Company Product Type and Application
  8. 3.8 Global GABAB Receptor Agonists Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global GABAB Receptor Agonists Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 GABAB Receptor Agonists Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 GABAB Receptor Agonists Market by Type
  1. 4.1 GABAB Receptor Agonists Type Introduction
  2. 4.1.1 Baclofen
  3. 4.1.2 γ-hydroxybutyrate(GHB)）
  4. 4.2 Global GABAB Receptor Agonists Sales Volume by Type
  5. 4.2.1 Global GABAB Receptor Agonists Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global GABAB Receptor Agonists Sales Volume by Type (2021-2032)
  7. 4.2.3 Global GABAB Receptor Agonists Sales Volume Share by Type (2021-2032)
  8. 4.3 Global GABAB Receptor Agonists Sales Value by Type
  9. 4.3.1 Global GABAB Receptor Agonists Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global GABAB Receptor Agonists Sales Value by Type (2021-2032)
  11. 4.3.3 Global GABAB Receptor Agonists Sales Value Share by Type (2021-2032)
5 GABAB Receptor Agonists Market by Application
  1. 5.1 GABAB Receptor Agonists Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global GABAB Receptor Agonists Sales Volume by Application
  6. 5.2.1 Global GABAB Receptor Agonists Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global GABAB Receptor Agonists Sales Volume by Application (2021-2032)
  8. 5.2.3 Global GABAB Receptor Agonists Sales Volume Share by Application (2021-2032)
  9. 5.3 Global GABAB Receptor Agonists Sales Value by Application
  10. 5.3.1 Global GABAB Receptor Agonists Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global GABAB Receptor Agonists Sales Value by Application (2021-2032)
  12. 5.3.3 Global GABAB Receptor Agonists Sales Value Share by Application (2021-2032)
6 GABAB Receptor Agonists Regional Sales and Value Analysis
  1. 6.1 Global GABAB Receptor Agonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GABAB Receptor Agonists Sales by Region (2021-2032)
  3. 6.2.1 Global GABAB Receptor Agonists Sales by Region: 2021-2026
  4. 6.2.2 Global GABAB Receptor Agonists Sales by Region (2027-2032)
  5. 6.3 Global GABAB Receptor Agonists Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global GABAB Receptor Agonists Sales Value by Region (2021-2032)
  7. 6.4.1 Global GABAB Receptor Agonists Sales Value by Region: 2021-2026
  8. 6.4.2 Global GABAB Receptor Agonists Sales Value by Region (2027-2032)
  9. 6.5 Global GABAB Receptor Agonists Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America GABAB Receptor Agonists Sales Value (2021-2032)
  12. 6.6.2 North America GABAB Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe GABAB Receptor Agonists Sales Value (2021-2032)
  15. 6.7.2 Europe GABAB Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific GABAB Receptor Agonists Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific GABAB Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America GABAB Receptor Agonists Sales Value (2021-2032)
  21. 6.9.2 South America GABAB Receptor Agonists Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa GABAB Receptor Agonists Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa GABAB Receptor Agonists Sales Value Share by Country, 2025 VS 2032
7 GABAB Receptor Agonists Country-level Sales and Value Analysis
  1. 7.1 Global GABAB Receptor Agonists Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global GABAB Receptor Agonists Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global GABAB Receptor Agonists Sales by Country (2021-2032)
  4. 7.3.1 Global GABAB Receptor Agonists Sales by Country (2021-2026)
  5. 7.3.2 Global GABAB Receptor Agonists Sales by Country (2027-2032)
  6. 7.4 Global GABAB Receptor Agonists Sales Value by Country (2021-2032)
  7. 7.4.1 Global GABAB Receptor Agonists Sales Value by Country (2021-2026)
  8. 7.4.2 Global GABAB Receptor Agonists Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt GABAB Receptor Agonists Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt GABAB Receptor Agonists Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt GABAB Receptor Agonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Xi'an Libang Pharmaceuticals
  2. 8.1.1 Xi'an Libang Pharmaceuticals Company Information
  3. 8.1.2 Xi'an Libang Pharmaceuticals Business Overview
  4. 8.1.3 Xi'an Libang Pharmaceuticals GABAB Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Xi'an Libang Pharmaceuticals GABAB Receptor Agonists Product Portfolio
  6. 8.1.5 Xi'an Libang Pharmaceuticals Recent Developments
  7. 8.2 Xi'an Hanfeng Pharmaceuticals
  8. 8.2.1 Xi'an Hanfeng Pharmaceuticals Company Information
  9. 8.2.2 Xi'an Hanfeng Pharmaceuticals Business Overview
  10. 8.2.3 Xi'an Hanfeng Pharmaceuticals GABAB Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Xi'an Hanfeng Pharmaceuticals GABAB Receptor Agonists Product Portfolio
  12. 8.2.5 Xi'an Hanfeng Pharmaceuticals Recent Developments
  13. 8.3 Sun Pharma
  14. 8.3.1 Sun Pharma Company Information
  15. 8.3.2 Sun Pharma Business Overview
  16. 8.3.3 Sun Pharma GABAB Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sun Pharma GABAB Receptor Agonists Product Portfolio
  18. 8.3.5 Sun Pharma Recent Developments
  19. 8.4 Hemony Pharmaceutical
  20. 8.4.1 Hemony Pharmaceutical Company Information
  21. 8.4.2 Hemony Pharmaceutical Business Overview
  22. 8.4.3 Hemony Pharmaceutical GABAB Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hemony Pharmaceutical GABAB Receptor Agonists Product Portfolio
  24. 8.4.5 Hemony Pharmaceutical Recent Developments
  25. 8.5 Sichuan Ren'an Pharmaceuticals
  26. 8.5.1 Sichuan Ren'an Pharmaceuticals Company Information
  27. 8.5.2 Sichuan Ren'an Pharmaceuticals Business Overview
  28. 8.5.3 Sichuan Ren'an Pharmaceuticals GABAB Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sichuan Ren'an Pharmaceuticals GABAB Receptor Agonists Product Portfolio
  30. 8.5.5 Sichuan Ren'an Pharmaceuticals Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis GABAB Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novartis GABAB Receptor Agonists Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Nanjing Haina Pharmaceutical
  38. 8.7.1 Nanjing Haina Pharmaceutical Company Information
  39. 8.7.2 Nanjing Haina Pharmaceutical Business Overview
  40. 8.7.3 Nanjing Haina Pharmaceutical GABAB Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Nanjing Haina Pharmaceutical GABAB Receptor Agonists Product Portfolio
  42. 8.7.5 Nanjing Haina Pharmaceutical Recent Developments
  43. 8.8 China Resources Double Crane Pharmaceuticals
  44. 8.8.1 China Resources Double Crane Pharmaceuticals Company Information
  45. 8.8.2 China Resources Double Crane Pharmaceuticals Business Overview
  46. 8.8.3 China Resources Double Crane Pharmaceuticals GABAB Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 China Resources Double Crane Pharmaceuticals GABAB Receptor Agonists Product Portfolio
  48. 8.8.5 China Resources Double Crane Pharmaceuticals Recent Developments
  49. 8.9 Fuan Pharmaceutical Group
  50. 8.9.1 Fuan Pharmaceutical Group Company Information
  51. 8.9.2 Fuan Pharmaceutical Group Business Overview
  52. 8.9.3 Fuan Pharmaceutical Group GABAB Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Fuan Pharmaceutical Group GABAB Receptor Agonists Product Portfolio
  54. 8.9.5 Fuan Pharmaceutical Group Recent Developments
  55. 8.10 Chengdu Beite
  56. 8.10.1 Chengdu Beite Company Information
  57. 8.10.2 Chengdu Beite Business Overview
  58. 8.10.3 Chengdu Beite GABAB Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Chengdu Beite GABAB Receptor Agonists Product Portfolio
  60. 8.10.5 Chengdu Beite Recent Developments
  61. 8.11 Viatris
  62. 8.11.1 Viatris Company Information
  63. 8.11.2 Viatris Business Overview
  64. 8.11.3 Viatris GABAB Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Viatris GABAB Receptor Agonists Product Portfolio
  66. 8.11.5 Viatris Recent Developments
  67. 8.12 Jazz Pharmaceuicals
  68. 8.12.1 Jazz Pharmaceuicals Company Information
  69. 8.12.2 Jazz Pharmaceuicals Business Overview
  70. 8.12.3 Jazz Pharmaceuicals GABAB Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Jazz Pharmaceuicals GABAB Receptor Agonists Product Portfolio
  72. 8.12.5 Jazz Pharmaceuicals Recent Developments
  73. 8.13 Hikma
  74. 8.13.1 Hikma Company Information
  75. 8.13.2 Hikma Business Overview
  76. 8.13.3 Hikma GABAB Receptor Agonists Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Hikma GABAB Receptor Agonists Product Portfolio
  78. 8.13.5 Hikma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GABAB Receptor Agonists Value Chain Analysis
  2. 9.1.1 GABAB Receptor Agonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GABAB Receptor Agonists Sales Mode & Process
  6. 9.2 GABAB Receptor Agonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GABAB Receptor Agonists Distributors
  9. 9.2.3 GABAB Receptor Agonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst